Why overall survival should not be the sole valid primary endpoint of phase 3 ovarian cancer chemotherapy trials

✍ Scribed by Maurie Markman

• Book ID: 113961164
• Publisher: Elsevier Science
• Year: 2007
• Tongue: English
• Weight: 98 KB
• Volume: 106
• Category: Article
• ISSN: 0090-8258
• DOI: 10.1016/j.ygyno.2007.06.005